Literature DB >> 17156134

On-demand therapy for gastroesophageal reflux disease.

David C Metz1, John M Inadomi, Colin W Howden, Sander J Veldhuyzen van Zanten, Peter Bytzer.   

Abstract

The following pages summarize the proceedings of a symposium held in May 2006 on the emerging role of on-demand therapy for gastroesophageal reflux disease (GERD). Medical therapy for GERD has undergone significant change in recent years with the advent of effective, but expensive, antisecretory agents. On-demand (patient-driven) therapy is attractive to payers and patients, because it appears to be both cost-effective and convenient. Many individuals appear to accept occasional symptomatic breakthrough in exchange for personal control of their disease. On-demand therapy should be distinguished from intermittent therapy, which is either patient- or physician-driven, but which requires intermittent episodes of continuous therapy followed by discontinuation until symptoms recur. Proton pump inhibitors appear to be effective on-demand agents despite theoretical pharmacodynamic limitations for this class of drug. The available data support the use of on-demand therapy for GERD in uninvestigated reflux disease, nonerosive reflux disease, and possibly mild esophagitis as well. On-demand therapy should not be considered for patients with severe esophagitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17156134     DOI: 10.1111/j.1572-0241.2006.00998.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  24 in total

1.  Overutilization of proton-pump inhibitors: what the clinician needs to know.

Authors:  Joel J Heidelbaugh; Andrea H Kim; Robert Chang; Paul C Walker
Journal:  Therap Adv Gastroenterol       Date:  2012-07       Impact factor: 4.409

Review 2.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

3.  Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers.

Authors:  Hatsushi Yamagishi; Tomoyuki Koike; Shuichi Ohara; Toru Horii; Ryousuke Kikuchi; Shigeyuki Kobayashi; Yasuhiko Abe; Katsunori Iijima; Akira Imatani; Kaori Suzuki; Takanori Hishinuma; Junichi Goto; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

4.  Balancing the risks and benefits of proton pump inhibitors.

Authors:  James M Gill; Marty S Player; David C Metz
Journal:  Ann Fam Med       Date:  2011 May-Jun       Impact factor: 5.166

5.  Proton pump inhibitors: use, misuse and concerns about long-term therapy.

Authors:  T P Rakesh
Journal:  Clin J Gastroenterol       Date:  2011-02-18

6.  Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial).

Authors:  Abhijeet Waghray; Nisheet Waghray; Adam T Perzynski; Mark Votruba; M Michael Wolfe
Journal:  Dig Dis Sci       Date:  2018-08-09       Impact factor: 3.199

Review 7.  NERD: an umbrella term including heterogeneous subpopulations.

Authors:  Edoardo Savarino; Patrizia Zentilin; Vincenzo Savarino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

Review 8.  The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.

Authors:  Alan B R Thomson
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 9.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications.

Authors:  Joel J Heidelbaugh
Journal:  Ther Adv Drug Saf       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.